Showing 1,460 news articles about Pharmaceutical industry

Filters Content type: Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Pharmaceutical industry

Gilead Sciences, after long battle against HIV drug fraudsters, scores $175.2M in judgements

Editor's pick
FiercePharma
13 March 2023
New & experimental HIV treatments

Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection

Editor's pick
Merck press release
23 February 2023
Pharmaceutical industry

Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table

Editor's pick
FiercePharma
23 February 2023
HIV treatment for children & young people

ViiV Healthcare receives EU Marketing Authorisation for Triumeq PD

Editor's pick
ViiV press release
22 February 2023
Pharmaceutical industry

Big pharma must value African lives above profits, warns head of UNAIDS

Editor's pick
The Guardian
16 February 2023
Pharmaceutical industry

Gilead Sciences Commends Convictions in Counterfeiting Scheme, Pledges Continued Commitment to Protect Patients

Editor's pick
Gilead Sciences press release
10 February 2023
Pharmaceutical industry

David J. Miller and Minnesota Independent Cooperative, Inc., Convicted in Multi-Million-Dollar Prescription Drug Diversion Scheme

Editor's pick
FDA
30 January 2023
Activism & civil society

Grassroots AIDS activists fought for and won affordable HIV treatments around the world – but PEPFAR didn't change governments and pharma

Editor's pick
The Conversation
25 January 2023
Pharmaceutical industry

India’s lax oversight of pharmaceutical manufacturing imperils health around the world

Editor's pick
STAT
9 January 2023
Pharmaceutical industry

Gilead runs new 'HIV is not a crime' TV ad with André De Shields

Editor's pick
FiercePharma
5 January 2023
The search for a cure

Researchers Study CRISPR Gene Editing to Cure HIV

Editor's pick
POZ
29 December 2022
Pharmaceutical industry

CytoDyn’s former CEO indicted for securities fraud. His misleading statements hurt patients even more than investors

Editor's pick
STAT
26 December 2022
Pharmaceutical industry

Ex-Cytodyn CEO, Amarex CEO hit with multiple fraud charges

Editor's pick
FierceBiotech
26 December 2022
Injectable & long-acting HIV treatment

FDA Approves New HIV Drug for Adults with Limited Treatment Options

Editor's pick
FDA
22 December 2022
Access to healthcare

CHAI 2022 report on global access to ART

Editor's pick
i-Base
19 December 2022
Health services & systems

US: Blue Cross and Blue Shield Accused of Placing Most HIV Drugs into Highest Tiers

Editor's pick
POZ
9 December 2022
Access to healthcare

More than 100 low- and middle-income countries have now received the WHO-recommended treatment for HIV thanks to access-oriented voluntary licensing agreements

Editor's pick
Medicines Patent Pool
1 December 2022
Pharmaceutical industry

Injections against HIV could be manufactured locally and cheaply, says Aspen Pharmacare

Editor's pick
GroundUp
1 December 2022
Injectable & long-acting PrEP

MSF: ViiV must make groundbreaking HIV prevention injection affordable and available

Editor's pick
MSF
29 November 2022
Access to healthcare

2022 HIV Market Report: The state of the HIV market in low- and middle-income countries

Editor's pick
Clinton Health Access Initiative
17 November 2022
Finance & funding

Good news: South African HIV medicine prices have decreased dramatically!

Editor's pick
GroundUp
17 November 2022
Pharmaceutical industry

Index finds more pharma companies moving to address access to medicine. Will they now go further?

Editor's pick
Access to Medicine Foundation
17 November 2022
Injectable & long-acting PrEP

Delays in global, affordable access to long-acting, injectable HIV medicines would cost lives, say AIDS campaigners

Editor's pick
UNAIDS
17 November 2022
Access to healthcare

UK–India trade deal could “jeopardise” generic medicines

Editor's pick
The Lancet (requires free registration)
12 November 2022